| Assessment Status |
Rapid Review Complete |
| HTA ID |
26027 |
| Drug |
Remibrutinib |
| Brand |
(Rhapsido®) |
| Indication |
For the treatment of chronic spontaneous urticaria in adult patients with inadequate response to H1 antihistamine treatment. |
| Rapid review commissioned |
29/05/2026 |
| Rapid review completed |
02/07/2026 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of remibrutinib (Rhapsido®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
